Poster: MM-181 CARTITUDE-1: Two-Year Post Last Patient in (LPI) Results From the Phase 1b/2 Study of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
In: Clinical Lymphoma, Myeloma and Leukemia, Jg. 22 (2022-10-01), Heft Supplement 2, S. S179
unknown
Zugriff:
Titel: |
Poster: MM-181 CARTITUDE-1: Two-Year Post Last Patient in (LPI) Results From the Phase 1b/2 Study of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
|
---|---|
Autor/in / Beteiligte Person: | Usmani, Saad Z ; Martin, Thomas ; Berdeja, Jesus G ; Jakubowiak, Andrzej ; Agha, Mounzer ; Cohen, Adam D ; Deol, Abhinav ; Htut, Myo ; Lesokhin, Alexander ; Munshi, Nikhil C ; O'Donnell, Elizabeth ; Jackson, Carolyn C ; Yeh, Tzu-min ; Banerjee, Arnob ; Zudaire, Enrique ; Madduri, Deepu ; Zhou, Changwei ; Pacaud, Lida ; Lin, Yi ; Jagannath, Sundar |
Zeitschrift: | Clinical Lymphoma, Myeloma and Leukemia, Jg. 22 (2022-10-01), Heft Supplement 2, S. S179 |
Veröffentlichung: | 2022 |
Medientyp: | unknown |
ISSN: | 2152-2650 (electronic) |
DOI: | 10.1016/S2152-2650(22)01099-0 |
Sonstiges: |
|